Novartis, Sanofi, Novo Nordisk Sign Major Biotech Deals
Novartis, Sanofi, and Novo Nordisk have signed significant deals this week, focusing on experimental autoimmune drugs, obesity pills, and cancer combinations. Novartis and Novo Nordisk acquired early-stage RNA and oral metabolic assets in China, while Sanofi expanded its inflammation franchise.